Abstract:
:Fluctuations in motor performance are the major problems in chronic management of Parkinson's disease. Most of these fluctuations reflect the decline of levodopa availability. As a consequence, levodopa dosage might be increased and the interdose interval progressively shortened. The postsynaptic dopamine receptors at this point are exposed to a nonphysiologic shift in dopamine level, which may induce changes at the receptor site and contribute to the appearance of "on-off" phenomena and dyskinesias. We compared a group of 18 patients treated for 60 consecutive months with continuous subcutaneous lisuride infusion with a group of 20 patients treated with conventional oral levodopa treatment. The clinical evaluations performed during the study showed in the lisuride group only a worsening of dyskinesias, whereas the other symptoms remained unchanged. In the other group the evaluation scores showed a significant worsening of all long-term treatment complications. The slow-release preparations of levodopa may ensure a more continuous dopaminergic stimulation than standard formulations. However, the use of these compounds is difficult in severely fluctuating patients because the lack of a plasma peak level usually leads to a very long delay before patients turn "on." We studied the pharmacokinetic and clinical effects of the two slow-release preparations of levodopa [Madopar HBS and Sinemet controlled-release (CR)] and a combination of Sinemet CR plus standard Sinemet in 13 fluctuating parkinsonian patients. The results of this study show that the combination of standard Sinemet and Sinemet CR ensures a more prolonged clinical effect with a very short latency to the "on" phase.
journal_name
Clin Neuropharmacoljournal_title
Clinical neuropharmacologyauthors
Stocchi F,Patsalos PN,Berardelli A,Barbato L,Bonamartini A,Manfredi M,Ruggieri Ssubject
Has Abstractpub_date
1994-01-01 00:00:00pages
S7-13eissn
0362-5664issn
1537-162Xjournal_volume
17 Suppl 2pub_type
杂志文章abstract:OBJECTIVES:A number of research studies support the weight loss effects of metformin and topiramate for obese people with schizophrenia. However, only a few studies have addressed the sustainability of the body weight reduction after discontinuation of these drugs. Moreover, head-to-head studies are still lacking. The ...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/WNF.0000000000000188
更新日期:2016-11-01 00:00:00
abstract::Interferons are a set of cytokines that activate antiviral responses by the body's immune cells and have been a mainstay of treatment of hepatitis C. Well-known neuropsychiatric effects of interferons include depression, irritability, and impaired concentration. A condition reported rarely in association with this tre...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/WNF.0000000000000120
更新日期:2016-01-01 00:00:00
abstract:OBJECTIVES:Neurosyphilis, an infectious neuroinflammatory disorder, could cause diverse neuropsychiatric symptoms mimicking disorders of schizophrenia and dementia; hence, it is known as the "chameleon of psychiatry." Here, we present a subject with neurosyphilis with schizophrenic features and share the treatment outc...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000347
更新日期:2019-07-01 00:00:00
abstract:OBJECTIVE:Neuroleptic malignant syndrome was induced by aripiprazole in a 12 1/2-year-old boy. The patient had a history of reactive airway disease, pervasive developmental disorder, and learning disability. METHOD:The patient was interviewed and examined, and additional history was taken from the medical records. The...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/01.WNF.0000240941.13876.5E
更新日期:2007-01-01 00:00:00
abstract:OBJECTIVES:Ponezumab is a humanized antiamyloid beta (Aβ) monoclonal antibody designed to treat Alzheimer disease (AD). METHODS:This randomized, double-blind, single-dose-escalation study evaluated the safety, pharmacokinetics, and pharmacodynamics of 0.1, 0.3, 1, 3, and 10 mg/kg ponezumab (n = 4, 4, 4, 6, and 8, resp...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1097/WNF.0b013e31827db49b
更新日期:2013-01-01 00:00:00
abstract::This review examines the features of the 16 randomized controlled trials that have been published on the use of oral tacrine for treating probable Alzheimer's disease and explores the methodologic problems associated with these studies. Patient selection using the standard National Institute of Neurological and Commun...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:
更新日期:1998-01-01 00:00:00
abstract::Preclamol, the (-)enantiomer of 3-PPP (= 3(3-hydroxyphenyl)-N-n-propyl piperidine), has a selective dopamine autoreceptor- and postsynaptic mixed agonist-antagonist profile. Its action on patients with disabling on-off parkinsonian fluctuations has been studied and compared with those of placebo and subcutaneous apomo...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:
更新日期:1993-12-01 00:00:00
abstract::We report on a schizophrenic patient whose tardive dystonia, delusions, and auditory hallucinations showed remarkable concurrent improvement after replacing haloperidol with risperidone. The present finding suggests that the 5-hydroxytryptamine-2 (5-HT2) antagonistic action of risperidone has brought about the improve...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:
更新日期:1998-01-01 00:00:00
abstract::Patients with Parkinson's disease (PD) can experience cognitive impairment. There are currently no medications indicated for the treatment of cognitive impairment in PD. Clinicians are faced with the dilemma as to whether or not to treat patients with PD with the acetylcholinesterase inhibitors that are currently appr...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-200211000-00002
更新日期:2002-11-01 00:00:00
abstract::Modafinil is a psychostimulant compound that is just now becoming available in many countries for treatment of narcoleptic and hypersomnic patients. Whereas sleep attacks and drowsiness can be effectively improved, the drug does not sufficiently reduce cataplectic seizures. It therefore is often used in combination wi...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:
更新日期:1998-03-01 00:00:00
abstract:OBJECTIVE:To review the current evidence on the effectiveness of second-generation antipsychotics (SGAs) in the treatment of tardive dystonia (TDt) and give recommendations for treatment. METHODS:Medline/PubMed/Psyclit/Embase database searches were conducted in January 2015, and a manual review of references within th...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/WNF.0000000000000106
更新日期:2015-09-01 00:00:00
abstract::Despite ongoing dispute over the pathophysiologic basis of migraine, the vasospastic theory of pathogenesis has brought to the forefront a promising class of new antimigraine agents, the Ca2+ channel antagonists. Voltage-dependent Ca2+ channels, integral membrane proteins that permit extracellular Ca2+ to enter cells ...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/00002826-198608000-00001
更新日期:1986-01-01 00:00:00
abstract::The mortality risk associated with cardiovascular disease is significantly increased in patients with major depression and panic disorder. The mechanism of this phenomenon is unclear. Thrombin is responsible for platelet aggregation and shape change, and it plays a significant role in the development of thromboembolic...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00002826-200007000-00002
更新日期:2000-07-01 00:00:00
abstract:OBJECTIVE:The purpose of this study is to investigate the safety and efficacy of aripiprazole in first-episode drug-naive patients with schizophrenia. METHODS:A total of 45 patients were enrolled in an open-label 12-week study. Dosing was determined by clinical judgment. The main efficacy measure was the Brief Psychia...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0b013e31817c6b06
更新日期:2009-05-01 00:00:00
abstract::A large number of patients with neurosyphilis present dementia with a progressive course and psychiatric symptoms such as depression, mania, and psychosis. Despite prompt and proper antibiotic treatment, the recovery is often incomplete, especially when tissue damage has occurred. We reported a patient with persisted ...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000094
更新日期:2015-07-01 00:00:00
abstract::The long-term effects of mesulergine, a new drug with dopamine agonistic properties, were studied in 28 patients with Parkinson's disease. In 18 patients with late side effects of levodopa, the addition of mesulergine (10.9 mg/day) induced significant decreases in the global (-48%), rigidity (-62%), and akinesia (-37%...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-198604000-00005
更新日期:1986-01-01 00:00:00
abstract::To determine the nature of the hormone dependency of meningioma, particularly whether progestin receptor (PR) and tumor growth are estrogen-dependent, we measured the cytosol estrogen receptor (ER) and PR separately by an exchange assay with [3H]R 2858 (for ER) and [3H]RU 27987 (for PR) in 21 meningiomas. We correlate...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-198412000-00018
更新日期:1984-01-01 00:00:00
abstract::Sarcosinemia is a relatively rare autosomal recessive disorder that has a varied phenotypic presentation; rarely, it is associated with neurodevelopmental and neurological abnormalities. Sarcosine is a key intermediate in 1-carbon metabolism, and its elevation in blood and urine could reflect a deficient pool size of ...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/01.WNF.0000236767.46526.1F
更新日期:2006-11-01 00:00:00
abstract::The extensive use of the Unified Parkinson's Disease Rating Scale (UPDRS) has revealed low interrater reliability in some items and redundancy in others. In view of these shortcomings, we have structured a new scale that includes a zero-to three-point scale for each item in the evaluation of PD. The mental axis includ...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:
更新日期:1997-08-01 00:00:00
abstract::The latency of P300 "cognitive" event-related potentials changes if cholinergic activities of the central nervous system are pharmacologically manipulated. We tested the hypothesis that the new cholinesterase inhibitors donepezil (DPZ) and rivastigmine (Riv) may have an effect on the frequently abnormal P300 component...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00002826-200101000-00007
更新日期:2001-01-01 00:00:00
abstract:BACKGROUND:Serotonin syndrome (SS) is a potentially life-threatening condition that can be caused by use of proserotonergic drugs. Several studies have reported that combined administration of various medications may induce SS. We report a case of SS in a patient who was being treated with dopaminergic and noradrenergi...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000220
更新日期:2017-07-01 00:00:00
abstract:OBJECTIVES:To assess quantitatively the influence of rotigotine transdermal patch on daytime sleepiness, the most common adverse event by non-ergot dopamine agonists (DAs), in Parkinson disease (PD) patients. METHODS:An open-label study enrolled PD patients with unsatisfactory control of motor symptoms. Treatment with...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000110
更新日期:2015-11-01 00:00:00
abstract::Monoamine oxidase (MAO) inhibitors (MAOIs) provide effective alternative therapy for those patients with major depression who do not respond to tricyclic antidepressants or such related compounds as the selective serotonin reuptake inhibitors. This article reviews studies on the efficacy of both the classical MAOIs an...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:
更新日期:1993-01-01 00:00:00
abstract::Acute psychotic episodes represent critical situations during the course of schizophrenia. Olanzapine (OLZ), a second-generation antipsychotic, is efficacious in acute settings at dosages of 5 to 20 mg/d, and it can be considered a first-line treatment for patients with an acute episode of schizophrenia. The aim of th...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/01.WNF.0000220819.71231.96
更新日期:2006-05-01 00:00:00
abstract::Heart rate variability (HRV) reflects the cardiac autonomic regulation, and reduced HRV is considered a pathophysiological link between depression and cardiovascular mortality. So far, there is only limited information on the effects of venlafaxine and mirtazapine on HRV.We studied 28 nondepressed controls and 41 mode...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/WNF.0b013e3182a76fbb
更新日期:2013-11-01 00:00:00
abstract:OBJECTIVES:Treatment-resistant depression is a common occurrence in clinical practice as well as combination treatment with 2 different antidepressants. In the present case series, we study the effectiveness of the addition of reboxetine, during 12 weeks, to 14 outpatients diagnosed with major depressive disorder, acco...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/01.WNF.0000228211.19818.14
更新日期:2006-07-01 00:00:00
abstract:OBJECTIVE:There has been an increase in the European and North American schizophrenia literature discussing the high prevalence of metabolic syndrome induced by atypical antipsychotic agents. The aim of this article was to review available data on metabolic syndrome induced by atypical antipsychotic agents in patients ...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/WNF.0b013e31824d5288
更新日期:2012-05-01 00:00:00
abstract:OBJECTIVE:To describe an unusual case of camptocormia responding to levodopa. METHODS:We present a case of camptocormia with a sustained excellent response to levodopa in a patient with negative dopamine transporter and no DYT 5 genetic mutations. RESULTS:We present a 52-year-old man with 2 years' history of progress...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000024
更新日期:2014-03-01 00:00:00
abstract::The effect and clinical significance of tolcapone withdrawal on erythrocyte catechol-O-methyltransferase (COMT) activity, levodopa pharmacokinetics, and levodopa requirements were investigated in 59 patients with fluctuating parkinsonism who were randomized to receive placebo or tolcapone 100 or 200 mg three times dai...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:10.1097/00002826-200003000-00007
更新日期:2000-03-01 00:00:00
abstract::A case of a mentally retarded patient with sporadic paroxysmal dystonia, unresponsive to anticonvulsant therapy, is described. He had a long-standing history of neuroleptic drug intake. Trihexyphenidyl in a total daily dosage of 20 mg totally suppressed the crises. ...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-198708000-00007
更新日期:1987-08-01 00:00:00